AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) has provided an update. AIM Vaccine Co., Ltd. has received approval from the U.S. FDA to conduct ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older.

Researchers have determined in a new study that the recombinant zoster vaccine (RZV) offers good protection from herpes ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

Low influenza vaccine uptake in India despite high mortality rates; manufacturers scaling up production to meet growing ...

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...

Recently, AIM announced a comprehensive deployment to integrate the DeepSeek large model, particularly in vaccine development, utilizing DeepSeek in conjunction with generative models and deep ...

The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

But the shingles studies published in 2024, along with a host of new papers, add weight to an alternative decades-old ...